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Tyrosine kinases normally function as
tightly regulated switches in the signal
transduction network of the cell. If these
switches become stuck in the “on” posi-
tion, they have the potential to induce
oncogenic transformation. Members of
both the receptor and nonreceptor fami-
lies of tyrosine kinases can function in
this oncogenic role.
Receptor tyrosine kinases (RTKs),
such as EGFR and Erb-B2 (Her-2/Neu),
are membrane-spanning proteins that are
composed of an extracellular ligand bind-
ing domain, a transmembrane domain,
and a cytoplasmic domain that contains a
conserved catalytic kinase core and regu-
latory sequences. Unstimulated RTKs
remain in a monomeric form; ligand bind-
ing, however, induces dimerization, which
facilitates reciprocal trans-phosphoryla-
tion of the cytoplasmic domain of each the
monomeric components. trans-phosphor-
ylation in turn actuates the receptor’s
catalytic kinase function and creates
recruitment sites for downstream signal-
ing targets (Schlessinger, 2000).
There are three general mecha-
nisms by which RTKs can become onco-
genic, each of which gives rise to a
constitutively active dimeric form. (1) In
some cancers, genomic rearrangements
occur that generate proteins in which the
cytoplasmic domain of a receptor tyro-
sine kinase is fused to a portion of a sec-
ond protein that maintains the chimera in
a stable dimer. (2) Alternately, as a con-
sequence of gene amplification, certain
receptor tyrosine kinases are overex-
pressed in tumor cells, which leads to
spontaneous, ligand-independent dimer-
ization. (3) Finally, some receptor tyro-
sine kinases acquire point mutations that
allow them to dimerize in a ligand-inde-
pendent manner (Blume-Jensen and
Hunter, 2001).
Nonreceptor, or cytoplasmic, tyro-
sine kinases, such as Abl, Src, and Lck,
lack extracellular and transmembrane
domains. The mechanisms by which
their activity is regulated are varied, and
accordingly, so are the mechanisms by
which they undergo oncogenic activa-
tion. Some are rendered constitutively
active by fusion to a dimerizing partner,
while others are transformed to oncopro-
teins when they acquire mutations that
disrupt autoinhibitory functions (Blume-
Jensen and Hunter, 2001).
Like other dominantly acting onco-
proteins, oncogenic tyrosine kinases
(OTKs) promote proliferation, invasion,
and metastasis. However, a unique char-
acteristic of OTKs is that they tend to ren-
der cells extraordinarily resistant to DNA
damage-induced apoptosis (Skorski,
2002). This is manifested clinically in the
finding that cancers in which OTKs are
expressed are usually highly resistant to
treatment with conventional antineoplas-
tic agents. Although it is likely that several
mechanisms contribute to this resistance,
a consistent finding is that oncogenic
tyrosine kinases induce markedly
increased expression of the antiapoptotic
protein Bcl-xL, and that the increased
expression is an important component of
the resistance to treatment.
A role for Bcl-xL was first suggested
when it was found that expression of Erb-
B2 (Her-2/Neu) in an estrogen receptor
(ER)-positive breast cancer cell line
increased the cellular level of Bcl-xL and
rendered the cells resistant to tamoxifen-
induced apoptosis (Kumar et al., 1996).
This was an intriguing finding, because
high-level expression of Erb-B2 in ER-
positive breast cancer is associated with
resistance to endocrine therapy. A more
direct demonstration of the role of the
increased expression of Bcl-xL in OTK-
induced resistance was provided by a
subsequent study in which it was found
that Bcr-Abl expression in a promyelocyt-
ic cell line resulted in increased expres-
sion of Bcl-xL and resistance to a variety
of apoptosis-inducing agents and that
inhibition of Bcl-xL expression with anti-
sense restored susceptibility (Amarante-
Mendes et al., 1998). Several other
potentially oncogenic tyrosine kinases
also upregulate Bcl-xL expression, includ-
ing EGFR (Karni et al., 1999), c-Src
(Karni et al., 1999), and ALK (Zamo et al.,
2002). Finally, the Bcr-Abl tyrosine kinase
inhibitor STI 571 is effective in killing
tumor cells at least in part because it
downregulates cellular Bcl-xL levels
(Horita et al., 2000; Oetzel et al., 2000).
When considered together, these find-
ings clearly implicate the antiapoptotic
activity of Bcl-xL as an important compo-
nent of the treatment resistance of
tumors that express OTKs.
Now, a new dimension has been
added to our understanding of this resis-
tance. In this issue of Cancer Cell, Zhao
and coworkers present the findings of
studies in which they used a transgenic
mouse model of T cell lymphoma to dis-
sect the components of the transforming
function of an activated form of the Src-
related tyrosine kinase Lck (Zhao et al.,
2004). In one study, they compared the
effects of two different levels of Lck activity
on the response to γ radiation and etopo-
side. Remarkably, the authors found that
even though the p53 signaling pathway
was equally responsive to treatment 
in thymocytes expressing either 
“intermediate activity” (higher activity than
wild-type Lck, but nononcogenic) or
“hyperactive” (oncogenic) Lck, and both
levels of Lck activity induced expres-
sion of similar levels of Bcl-xL, the
“hyperactive” Lck was strikingly more
effective in preventing both γ radiation-
induced and etoposide-induced apop-
tosis. When the authors set out to
define the mechanism underlying this
difference, they found that whereas the
“intermediate activity” Lck had no
effect on γ radiation-induced and
etoposide-induced deamidation of Bcl-
xL, Bcl-xL deamidation was completely
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The discovery two decades ago that the Philadelphia chromosome encodes an oncogenic fusion of Bcr and Abl remains
among the most important contributions to our understanding of the process of malignant transformation. We now know
that Bcr-Abl is one of more than 30 aberrantly activated tyrosine kinases that are expressed in a variety of tumors.
Conventional treatment of the tumors in which these proteins are expressed is usually doomed to failure because the acti-
vated tyrosine kinases render the tumor cells stubbornly resistant to apoptosis. In this context, it is notable that Zhao and
coworkers have uncovered a novel weapon in the resistance armamentarium of these rogue kinases, the suppression of
the inactivating deamidation of Bcl-xL (this issue of Cancer Cell).
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suppressed by the “hyperactive” Lck
(Figure 1).
Deamidation is a posttranslational
modification in which an asparagine is
converted into an aspartate. It was
recently found that Bcl-xL undergoes
deamidation at two asparagines in
response to treatment with antineoplas-
tic agents in a variety of tumor cells and
that the inhibition of Bcl-xL deamidation
increases the cells’ resistance to the
effects of these agents (Deverman et al.,
2002). This implies that deamidation
decreases the antiapoptotic activity of
Bcl-xL. Consistent with this is the finding
in the current study that deamidation dis-
rupts the ability of Bcl-xL to bind to the
proapoptotic Bcl-2 family member Bim. It
had previously been shown that the anti-
apoptotic activity of Bcl-xL is dependent
upon its ability to bind to Bim and related
proteins (Cheng et al., 2001). Therefore,
Zhao and coworkers have provided fur-
ther evidence that deamidation serves to
inactivate Bcl-xL.
The finding that oncogenic Lck both
suppresses Bcl-xL deamidation and ren-
ders the cell resistant to apoptosis raises
the possibility that suppression of Bcl-xL
deamidation contributes to the resis-
tance that is characteristic of OTK-
induced tumors. This is supported by the
finding that deamidation of Bcl-xL is sup-
pressed in hepatoccellular carcinoma—
a tumor in which OTKs are expressed
that is notoriously difficult to treat
(Takehara and Takahashi, 2003). These
are exciting findings because they sug-
gest that stimulation of Bcl-xL deamida-
tion will at least in part overcome
OTK-induced resistance. Thus, a new
avenue for treatment has been opened.
The challenge now is to delineate the
mechanism by which deamidation of Bcl-
xL is regulated and to determine how it is
suppressed by OTKs.
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Figure 1. Model for oncogenic Lck-induced resistance to apoptosis
When Lck activity is low (normal), Bcl-xL is at a basal level and susceptible to deamidation, which leaves the cell susceptible to DNA-damaging
agent-induced apoptosis. If Lck activity is increased, but below an oncogenic level, the level of Bcl-xL is increased, but the Bcl-xL remains suscep-
tible to deamidation, so the cell displays only a low level of resistance to DNA-damaging agent-induced apoptosis. If Lck activity exceeds the
oncogenic threshold, the level of Bcl-xL is increased and deamidation of the Bcl-xL is suppressed, which renders the cell highly resistant to DNA-
damaging agent-induced apoptosis. It is important to note that it is likely that other effects of increased Lck activity also contribute to resistance.
